# Changes in Health-Related Quality of Life in Vivax Malaria Patients: Measurement and Valuation in Indonesia and Cambodia

**Ery Setiawan,** Tripura R, Adhikari B, Pasaribu AP, Degaga T, Teferi T, Tedesse D, Ghanchi N, Beg MA, Mnjala H, Lee G, Thriemer K, Devine A



## Introduction

This study aimed to evaluate whether the EQ-5D-5L survey was sensitive to changes in quality of life among patients with acute uncomplicated vivax malaria from time of diagnosis to recovery after treatment.

#### Method

- The EQ-5D-5L was used alongside an ongoing clinical trial for vivax malaria patients in Cambodia and Indonesia at three time points: day 0 when they were acutely sick, day 21, and 6 months.
- We valued health states with local value sets (using Thailand's value set for Cambodia) to get the index scores.
- Linear regression was performed to assess the change in mean index score between time points.

### Result

- At day 0, over half of the patients in Cambodia reported pain/discomfort (75%), problems with usual activities (65%), and mobility (54%), while only 27% experienced problems in self-care and anxiety. For Indonesia, 75% of patients reported pain/discomfort, but less than half reported issues with usual activities (48%), mobility (32%), anxiety/depression (26%), and self-care (13%).
- Linear regression showed a significant difference between the mean index score at baseline (day 0) and both follow-up time points (p-value <0.05).




Table 1. The EQ5D-5L Index Score by Country Setting and Time of Measurement

	Indonesia (N = 149)		Cambodia (N = 220)	
	Mean	SD	Mean	SD
Day 0 Day 21 Month 6	0.816 0.985 0.997	0.147 0.052 0.015	0.814 0.946 0.993	0.174 0.123 0.038

# **Conclusion and Future Direction**

- We found significant changes in quality of life from acute illness with vivax malaria to recovery, demonstrating that the EQ-5D-5L instrument is sensitive enough to capture differences in quality of life in these settings.
- With decreasing rates of malaria mortality and a growing number of available value sets, future malaria studies should consider including the EQ-5D-5L to capture morbidity.